Quick Facts
HIV-infected people exposed to tuberculosis are 30 to 50 times more likely to develop active TBDevices and Diagnostics
Sequella developed several technologies to fill gaps in TB diagnosis and therapy that will assist the company in developing new TB drugs and assure that any new TB drugs commercialized by Sequella will be used correctly. These technologies were, for the most part, developed entirely by grant support (*). We are actively looking for corporate partners for non-core assets that are not yet licensed for commercial development:
| *Event Marker System A system to measure events (such as medication ingestion) via transdermal detection of a marker. A prototype assessed in a 'proof-of-principle' clinical study at Wills Eye Institute in Philadelphia, PA. demonstrated that the non-invasive, transdermal system readily detected a fluorescent marker in peripheral blood. Sequella is actively looking for a corporate partner to commercialize the device to monitor drug regimen compliance and illegal counterfeiting. |
|
| *B-SMART™ Antibiotic Susceptibility Test A platform IVD technology using a novel nucleic acid format to identify a bacterial pathogen and determine its antibiotic susceptibility pattern. Laboratory proof-of-principle is ongoing and funded by a grant. B-SMART™was licensed to LabCorp for the TB indication in the U.S., but is available for this indication outside the U.S. and for all other indications worldwide. For more information, please see our B-Smart™ Backgrounder. |
|
| Out-licensed Technologies *PrimaTB STAT-PAK® Lateral-flow serological TB Test for Non-human Primates developed with SBIR grants. Licensed to Chembio Systems, LI, NY, in 2007. |
|
